secwatch.observer — SEC 8-K summary
======================================

Issuer:     WEST PHARMACEUTICAL SERVICES INC (WST)
CIK:        0000105770
Form:       8-K
Filed at:   2024-07-25T23:59:59+00:00
Accession:  0000105770-24-000060
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

West Pharma Q2 net sales miss; slashes FY 2024 EPS guidance by over $1.20
-------------------------------------------------------------------------

- Q2 net sales $702.1M, down 6.9% YoY; reported diluted EPS $1.51 vs $2.06; adj. EPS $1.52 vs $2.11.
- Proprietary Products sales fell 9.4% to $559.7M; customer destocking continues, especially in Generics.
- FY 2024 net sales guidance cut to $2.87-2.90B from $3.00-3.025B; adj. EPS lowered to $6.35-6.65 from $7.63-7.88.
- First-half free cash flow fell 38.3% to $92.4M; company repurchased 1.24M shares for $454.1M at avg $366.53.
- Management expects organic growth to return in Q4 and 2025; capex guidance raised to $375M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/105770/000010577024000060/0000105770-24-000060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/105770/000010577024000060/wst-20240725.htm
  HTML page:      https://secwatch.observer/filing/0000105770-24-000060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer